164 related articles for article (PubMed ID: 34260595)
1. Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Ruggenenti P; Cortinovis M; Parvanova A; Trillini M; Iliev IP; Bossi AC; Belviso A; Aparicio MC; Trevisan R; Rota S; Perna A; Peracchi T; Rubis N; Martinetti D; Prandini S; Gaspari F; Carrara F; De Cosmo S; Tonolo G; Mangili R; Remuzzi G;
PLoS Med; 2021 Jul; 18(7):e1003691. PubMed ID: 34260595
[TBL] [Abstract][Full Text] [Related]
2. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
3. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
4. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Ruggenenti P; Trillini M; P Barlovic D; Cortinovis M; Pisani A; Parvanova A; Iliev IP; Ruggiero B; Rota S; Aparicio MC; Perna A; Peraro F; Diadei O; Gaspari F; Carrara F; Stucchi N; Martinetti D; Janez A; Gregoric N; Riccio E; Bossi AC; Trevisan R; Manunta P; Battaglia G; David S; Aucella F; Belviso A; Satta A; Remuzzi G;
Diabetes Obes Metab; 2019 May; 21(5):1177-1190. PubMed ID: 30793466
[TBL] [Abstract][Full Text] [Related]
5. Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
Hypertens Res; 2008 Jun; 31(6):1171-6. PubMed ID: 18716365
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
7. A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.
Daina E; Cravedi P; Alpa M; Roccatello D; Gamba S; Perna A; Gaspari F; Remuzzi G; Ruggenenti P
Nephron; 2015; 130(1):13-20. PubMed ID: 25895746
[TBL] [Abstract][Full Text] [Related]
8. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Waeber B; Aschwanden R; Sadecky L; Ferber P
J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
[TBL] [Abstract][Full Text] [Related]
9. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
10. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
[TBL] [Abstract][Full Text] [Related]
11. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
Katayama K; Nomura S; Ishikawa H; Murata T; Koyabu S; Nakano T
Kidney Int; 2006 Jul; 70(1):151-6. PubMed ID: 16710356
[TBL] [Abstract][Full Text] [Related]
12. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.
De Cosmo S; Motterlini N; Prudente S; Pellegrini F; Trevisan R; Bossi A; Remuzzi G; Trischitta V; Ruggenenti P;
Diabetes; 2009 Dec; 58(12):2920-9. PubMed ID: 19720797
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
14. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Bakris GL; Toto RD; McCullough PA; Rocha R; Purkayastha D; Davis P;
Kidney Int; 2008 Jun; 73(11):1303-9. PubMed ID: 18354383
[TBL] [Abstract][Full Text] [Related]
15. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
Saglimbene V; Palmer SC; Ruospo M; Natale P; Maione A; Nicolucci A; Vecchio M; Tognoni G; Craig JC; Pellegrini F; Lucisano G; Hegbrant J; Ariano R; Lamacchia O; Sasso A; Morano S; Filardi T; De Cosmo S; Pugliese G; Procaccini DA; Gesualdo L; Palasciano G; Johnson DW; Tonelli M; Strippoli GFM;
J Am Soc Nephrol; 2018 Dec; 29(12):2890-2899. PubMed ID: 30420421
[TBL] [Abstract][Full Text] [Related]
16. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
Segura J; Praga M; Campo C; Rodicio JL; Ruilope LM
J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
[TBL] [Abstract][Full Text] [Related]
17. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
BENEDICT Group
Control Clin Trials; 2003 Aug; 24(4):442-61. PubMed ID: 12865039
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
Morikawa A; Ishizeki K; Iwashima Y; Yokoyama H; Muto E; Oshima E; Sekiguchi M; Miura T; Itoh H; Haneda M
Clin Exp Nephrol; 2011 Dec; 15(6):848-53. PubMed ID: 21823043
[TBL] [Abstract][Full Text] [Related]
19. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
[TBL] [Abstract][Full Text] [Related]
20. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
Maione A; Nicolucci A; Craig JC; Tognoni G; Moschetta A; Palasciano G; Pugliese G; Procaccini DA; Gesualdo L; Pellegrini F; Strippoli GF;
J Nephrol; 2007; 20(6):646-55. PubMed ID: 18046666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
